CLINICAL TRIALS

WHAT IS A CLINICAL TRIAL?
A clinical trial is a type of research study that aims to explore whether a medical treatment is safe and effective for humans.

DO YOU NEED A CLINICAL TRIAL?
If you have liposarcoma progression despite the use of standard therapies and surgery, you or your doctor may want to investigate a clinical trial as an option for your treatment plan. While clinical trials are technically considered research, many liposarcoma patients have benefited from participation. Each clinical trial is designed for a specific purpose or condition.

WHAT ARE THE BENEFITS?

• The option of gaining access to new treatments after standard therapy fails.
• The opportunity to be the first to benefit from a new method under study.
• Receiving treatment at a major liposarcoma trial center.
• Close monitoring, advice, care, and support by a research team who has a better understanding of your disease or condition.
• The chance of helping future liposarcoma patients by contributing to medical research.

WHAT ARE THE RISKS?

• The new drug may not work for you.
• There may be unpleasant side effects as a response to the experimental treatment.
• Additional testing, time, and travel may be required.
• Some costs may not be covered by insurance companies.

 

CURRENT CLINICAL TRIALS:

CLINICAL TRIALS – UNITED STATES (RECRUITING):

Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors

• Locations: Gabrail Cancer Center, Canton, Ohio, United States, 44718
  Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States, 44195
• Status: RECRUITING
• Phase: 1/2
• Conditions: Liposarcoma, Dedifferentiated Liposarcoma, MDM2 inhibitor
• Intervention/Treatment: Drug: SA53-OS
• Brief Summary: This study is to assess the safety, efficacy, and pharmacokinetics of SA53-OS in adult participants with refractory solid tumors…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06578624

 

Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma

• Locations: Washington University School of Medicine, St. Louis, Missouri, 63110, United States
• Status: RECRUITING
• Phase: 1
• Conditions: Advanced Liposarcoma
• Intervention/Treatment: Drug: Zanzalintinib; Eribulin
• Brief Summary: This study is testing the safety and optimal dosing of combining zanzalintinib with eribulin in patients with advanced liposarcoma or leiomyosarcoma who have received prior treatment. The study also explores whether this combination may improve progression-free survival compared to eribulin alone based on historical data.
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06957431

 

BTX-A51 in Patients with Liposarcoma

• Locations: Brigham and Women’s Hospital, Boston, Massachusetts, 02215, United States; Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States
• Status: RECRUITING
• Phase: 1
• Conditions: Liposarcoma, Recurrent Liposarcoma, Metastatic Liposarcoma, Unresectable Liposarcoma, MDM2 Gene Amplification
• Intervention/Treatment: Drug: BTX-A51
• Brief Summary: This study is testing if the recommended dose of BTX-A51 is safe and tolerable in participants with liposarcoma…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06414434

 

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

• Locations: Houston Methodist Hospital, Houston, Texas, 77030, United States
• Status: RECRUITING
• Phase: 1
• Conditions: Liposarcoma
• Intervention/Treatment: 
• Brief Summary: This research study combines two different ways of fighting cancer: antibodies and T cells. This Phase 1 trial is evaluating the safety and early effectiveness of a novel CAR T-cell therapy engineered to target GPC3-positive solid tumors, enhanced with IL-15 and IL-21 to improve persistence and tumor-killing ability. It uses a dose-escalation design in adults with relapsed or refractory disease to determine a safe dose and assess preliminary anti-tumor response.
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06198296

 

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma

• Locations: Memorial Sloan Kettering Westchester, Harrison, New York, United States, 10604; Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10065
• Status: RECRUITING
• Phase: 1
• Conditions: Uveal Melanoma; Melanoma; Metastatic Uveal Melanoma; Metastatic Melanoma; Dedifferentiated Liposarcoma
• Intervention/Treatment: Biological: Lifileucel (LN-144/LN-145)
• Brief Summary: This study is a Phase 1 trial testing lifileucel (TIL therapy), a personalized immunotherapy made from a patient’s own immune cells. It includes adults with advanced cancers such as dedifferentiated liposarcoma after prior treatment. Patients have a tumor sample collected, followed by a one-time cell infusion and immune support therapy.
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05607095

 

Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

• Locations: MD Anderson Cancer Center, Houston, Texas, 77030, United States
• Status: RECRUITING
• Phase: 1
• Conditions: Synovial Sarcoma; Myxoid/Round Cell Liposarcoma
• Intervention/Treatment: Drug: Fludarabine phosphate; NY-ESO-1 TCR/IL-15 NK; Cyclophosphamide
• Brief Summary: The goal of this clinical research study is to find a recommended dose of donated NK cells that can be given along with chemotherapy to patients with advanced cancers. The safety and effects of this therapy will also be studied…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06083883

 

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

• Locations: Texas Children’s Hospital, Houston, Texas, 77030, United States
• Status: RECRUITING
• Phase: 1
• Conditions: Liver Cancer; Rhabdomyosarcoma; Malignant Rhabdoid Tumor; Liposarcoma; Wilms Tumor; Yolk Sac Tumor
• Intervention/Treatment: Genetic: CARE T cells; Drug: Cytoxan; Fludara
• Brief Summary: Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment. This research study uses special immune system cells called CARE T cells, a new experimental treatment …
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04715191

 

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

• Locations: National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, 20892, United States; Dana-Farber – Harvard Cancer Center LAO, Boston, Massachusetts, 02115, United States; Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109, United States (SUSPENDED); University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, 15232, United States; M D Anderson Cancer Center, Houston, Texas, 77030, United States
• Status: RECRUITING
• Phase: 1
• Conditions: Metastatic Dedifferentiated Liposarcoma; Metastatic Leiomyosarcoma; Metastatic Myxofibrosarcoma; Metastatic Sarcoma; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Unresectable Dedifferentiated Liposarcoma; Unresectable Leiomyosarcoma; Unresectable Myxofibrosarcoma; Unresectable Sarcoma; Unresectable Synovial Sarcoma; Unresectable Undifferentiated Pleomorphic Sarcoma
• Intervention/Treatment: Procedure: Biopsy; Procedure: Biospecimen Collection Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Drug: Pegylated Liposomal Doxorubicin Hydrochloride; Peposertib
• Brief Summary: This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sarcoma that has spread from where it first started, to other places in the body (metastatic), or cannot be removed by surgery (unresectable) and for which no known cure is available (advanced)…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05711615

 

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

• Locations: MD Anderson Cancer Center, Houston, Texas, 77030, United States
• Status: RECRUITING
• Phase: 1/2
• Conditions: Dedifferentiated Liposarcoma
• Intervention/Treatment: Drug: Abemaciclib; Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Docetaxel; Drug: GemcitabineBTX-A51
• Brief Summary: This phase I/II trial tests the side effects and best dose of abemaciclib when added to gemcitabine and compares the effectiveness of that treatment to the usual treatment of gemcitabine with docetaxel for the treatment of patients with soft tissue sarcoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) (phase 1) or patients with dedifferentiated liposarcoma (phase 2).
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06498648

 

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

• Locations: Lurie Children’s Hospital of Chicago, Chicago, Illinois, United States, 60611; Our Lady of the Lake Children’s Hospital, Baton Rouge, Louisiana, United States, 70809; Dana Farber Cancer Institute, Boston, Massachusetts, United States, 02215; Washington University Medical Center, St Louis, Missouri, United States, 63110; Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States, 45229; St. Jude Children’s Research Hospital, Memphis, Tennessee, United States, 38105
• Status: RECRUITING
• Phase: 1/2
• Conditions:  Non-rhabdomyosarcoma; Adipocytic Neoplasm; Liposarcoma
• Intervention/Treatment: Procedure: Surgical resection; Radiation: Proton beam radiation therapy; Drug: Pazopanib; Ifosfamide; Doxorubicin; Selinexor
• Brief Summary: The study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS)…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06239272

 

A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma

• Locations: Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States, 07920; Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States, 07748; Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States, 07645; Memorial Sloan Kettering Cancer Center Suffolk- Commack, Commack, New York, United States, 11725; Memorial Sloan Kettering Westchester, Harrison, New York, United States, 10604; Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10065; Memorial Sloan Kettering Nassau, Uniondale, New York, United States, 11553
• Status: RECRUITING
• Phase: 1/2
• Conditions: Well Differentiated Liposarcoma; Dedifferentiated Liposarcoma: Liposarcoma: Myxoid Liposarcoma; Round Cell Liposarcoma: Myxoid Pleomorphic Liposarcoma; Pleomorphic Liposarcoma; Unresectable Liposarcoma; Unresectable Dedifferentiated Liposarcoma; Unresectable Well Differentiated Liposarcoma
• Intervention/Treatment: Drug: Mirdametinib; Palbociclib
• Brief Summary: The purpose of this study is to find out whether mirdametinib in combination with palbociclib is an effective and safe treatment for…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06843967

 

A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma

• Locations: Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10065
• Status: RECRUITING
• Phase: 2
• Conditions: Soft Tissue Sarcoma
• Intervention/Treatment: Drug: Tigilanol Tiglate
• Brief Summary: This study is an open-label, single-arm study is evaluating the preliminary efficacy and safety of intratumoral tigilanol tiglate in adults with advanced or metastatic soft tissue sarcoma of the extremities or body wall. The trial focuses on tumor ablation and overall disease control, while also assessing safety, pharmacokinetics, and potential immune responses.
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05755113

 

Genomic Risk in Retroperitoneal Sarcoma

• Location: Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States
• Status: RECRUITING
• Phase: Not Applicable
• Conditions: Retroperitoneal Liposarcoma; Soft Tissue Sarcoma
• Intervention/Treatment: Other: Biospecimen sample collection during standard-of-care surgery
• Brief Summary: The protocol intends to explore the biology which may underlie recurrences of retroperitoneal liposarcoma. Surgery remains the only curative intent intervention for this disease…
  More information and eligibility requirements can be found here: STUDY: NCT06436846

 

CLINICAL TRIALS UNITED STATES & INTERNATIONAL (RECRUITING):

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

• Locations: UNITED STATES & UNITED KINGDOM (See link below for various location options.) Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10065; University of Texas MD Anderson Cancer Center, Houston, Texas, United States, 77030; Fred Hutchinson Cancer Center, Seattle, Washington, United States, 98109; UNITED KINGDOM
• Status: RECRUITING
• Phase: 1
• Conditions: Salivary Gland Tumor; Urothelial Carcinoma; Ovarian Carcinoma; Breast Cancer; Soft Tissue Sarcoma
• Intervention/Treatment: Drug: AVA6000
• Brief Summary: This is a first-in-human (FIH), Phase 1 open-label, multicentre dose escalation study investigating AVA6000 monotherapy administered…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04969835

 

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

• Locations: UNITED STATES & INTERNATIONAL (See link below for various location options.)
• Status: RECRUITING
• Phase: 1
• Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Non-small Cell Lung Cancer
• Intervention/Treatment: Drug: BGB-43395, Fulvestrant, Letrozole, Elacestrant
• Brief Summary: This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-43395.
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06120283

 

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors 

• Locations: UNITED STATES & CANADA (See link below for various location options.) Arnold Palmer Hospital for Children, Orlando, Florida, United States, 32806; St. Joseph’s Children’s Hospital, Tampa, Florida, United States, 33614; Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States, 96813; Children’s Mercy Hospitals and Clinics, Kansas City, Missouri, United States, 64108; Penn State Milton S. Hershey Medical Center and Children’s Hospital, Hershey, Pennsylvania, United States, 17033;  CANADA (See link below for various location options)
• Status: RECRUITING
• Phase: 1/2
• Conditions: Neuroblastoma Recurrent; Ewing’s Sarcoma Recurrent; Osteosarcoma Recurrent; Rhabdomyosarcoma Recurrent; Liposarcoma Recurrent
• Intervention/Treatment: Drugs: Silmitasertib; Irinotecan; Temozolomide; Vincristine
• Brief Summary: The purpose of this study is to evaluate the investigational drug, silmitasertib (a pill taken by mouth), in combination with FDA approved drugs for solid tumors…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06541262

 

First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma (ADCElerate1)

• Locations: UNITED STATES & INTERNATIONAL (See link below for various location options.)  University of Miami – Sylvester Comprehensive Cancer Center, Miami, Florida, United States, 33136;
  Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10065; University Of Texas MD Anderson Cancer Center, Houston, Texas, United States, 77030. See link below for various international location options.
• Status: RECRUITING
• Phase: 1/2
• Conditions: Metastatic Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma
• Intervention/Treatment: Biological: Antibody-drug conjugate (ADC)
• Brief Summary: The goal of this clinical trial is to learn about the safety, tolerability and efficacy of ADCE-D01.
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06797999

 

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma (STRASS2)

• Locations: United States, Australia, Canada, Cyprus, Czechia, Denmark, France, Germany, Italy, Japan, Netherlands, Poland, Spain, United Kingdom (See link below for various location options.)
• Status: RECRUITING
• Phase: 3
• Conditions:  Retroperitoneal Sarcoma; Liposarcoma; Leiomyosarcoma
• Intervention/Treatment: Procedure: Surgery; Drug: Preoperative chemotherapy
• Brief Summary: This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04031677

 

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

• Locations: United States, Canada, & Puerto Rico(See link below for various location options.)
• Status: RECRUITING
• Phase: 3
• Conditions:  Dedifferentiated Liposarcoma
• Intervention/Treatment: Procedure: Biospecimen Collection; Procedure: Diagnostic Imaging Testing; Drug: Doxorubicin; Procedure: Echocardiography Test; Procedure: Multigated Acquisition Scan; Biological: Pembrolizumab
• Brief Summary: This trial evaluates whether adding the immunotherapy pembrolizumab to standard doxorubicin chemotherapy improves outcomes compared to doxorubicin alone in patients with metastatic or unresectable dedifferentiated liposarcoma, undifferentiated pleomorphic sarcoma, and related poorly differentiated sarcomas. The study primarily measures progression-free survival and overall survival to determine if the combination approach provides a clinical benefit. For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06422806

 

CLINICAL TRIALS INTERNATIONAL (RECRUITING):

Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (TRASTS)

• Locations: FRANCE: Institut Bergonie, Bordeaux, 33000, France; Centre Leon Berard, Lyon, France; ITALY: Centro di Referimento Ocologico, Aviano, 33081, Italy (NOT YET RECRUITING); Istituto Ortopedico Rizzoli, Bologna, 40136, Italy (NOT YET RECRUITING); Candiolo Cancer Institute, Candiolo, 10060, Italy; Istituto Nazionale dei Tumori, Milan, 20133, Italy; Hospital Miguel Servet, Zaragoza, Aragon, 50009, Istituto Clinico Humanitas, Rozzano, Milan, Italy 20089, Italy (NOT YET RECRUITING), Italy  SPAIN: Hospital Sant Pau, Barcelona, Cataluña, 08041, Spain; Hospital Son Espases, Palma de Mallorca, Mallorca, 07010, Spain; Hospital Universitario Canarias, San Cristobal de la Laguna, Tenerife, 38320, Spain; Hospital Vall d’Hebron, Barcelona, 08035, Spain; Hospital Puerta de Hierro, Madrid, 28006, Spain; Hospital Universitario Gregorio Maranon, Madrid, 28007, Spain; Hospital Uniersitario La Paz, Madrid, 28046, Spain; Jimenez Di­az Foundation University Hospital, Madrid, Spain; Hospital Virgen del Roci­o, Sevilla, 41013, Spain
• Status: RECRUITING
• Phase: 1/2
• Conditions: Liposarcoma, Myxoid; Sarcoma, Soft Tissue; Leiomyosarcoma; Liposarcoma; Pleomorphic Liposarcoma
• Intervention/Treatment: Drug: Trabectedin; Radiation: Radiotherapy
• Brief Summary: Phase I-II trial that combines trabectedin plus radiotherapy for tumor reduction response measure in four cohorts of patients…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT02275286

 

APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors

• Locations: Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China; Cancer Hospital of The University of Chinese Academy of Sciences, Hangzhou, Zhejiang, 310005, China; Shanghai East Hospital (East Hospital affiliated to Tongji University), Shanghai, China
• Status: RECRUITING
• Phase: 1/2
• Conditions: Liposarcoma; Advanced Solid Tumor
• Intervention/Treatment: Drug: APG-115; Toripalimab
• Brief Summary: Part 1 is a phase Ib standard “3 + 3” design, will be employed to determine the MTD of APG-115 by assessing the DLT of APG-115 in combination with PD-1 inhibitor(toripalimab) in advanced solid tumors. Part 2 is a Simon two-stage phase II study design. At RP2D of APG-115 in combination with toripalimab in advanced liposarcoma, approximately 34 patients will be treated with the combination until disease progression, unacceptable toxicity, or another discontinuation criterion is met…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04785196

 

A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

• Locations: CHINA (See link below for various location options)
• Status: RECRUITING
• Phase: 1/2
• Conditions: Advanced Solid Tumors
• Intervention/Treatment: Drug: SPH4336; Cadonilimab
• Brief Summary: This is a randomized, Open-label, Phase Ib/IIa study to evaluate the efficacy and safety of SPH4336 monotherapy or in combination with Cadonilimab in the patients with selected advanced solid tumors.…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05944224

 

Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated Liposarcoma (PERELI)

• Locations: NORWAY: Oslo University Hospital HF, Oslo, Norway; SWEDEN: Sahlgrenska University Hospital, Göteborg, Sweden; Skane University Hospital, Lund, Sweden; Karolinska Universitetssjukhuset, Stockholm, Sweden
• Status: RECRUITING
• Phase: 2
• Conditions: Dedifferentiated Liposarcoma
• Intervention/Treatment: Drugs: Pemigatinib; Retifanlimab
• Brief Summary: Dedifferentiated liposarcomas (DDLPS) are aggressive soft tissue sarcomas…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06389799

 

Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas (ESPACE)

• Locations: Institut du Cancer de Montpellier – Val d’Aurelle, Montpellier, 34298, France
• Status: RECRUITING
• Phase: Not Applicable
• Conditions: Liposarcoma, Atypical Lipomatous Tumor
• Intervention/Treatment: Diagnostic Test: Blood sampling
• Brief Summary: The main objective of this project is to identify a new non-invasive biological test for the diagnosis of LPS by measuring circulating serine levels. The current gold standard is the detection of Mdm2 amplification by the FISH…
  More information and eligibility requirements can be found here: STUDY: NCT04224064

 

International Prospective Registry on Local Treatment Approaches in MLS

• Locations: The Netherlands Cancer Institute, Amsterdam, 1066CX, Netherlands
• Status: RECRUITING
• Phase: Not Applicable
• Conditions:  Liposarcoma, Myxoid Liposarcoma
• Intervention/Treatment: Procedure: Surgery; Radiation: Preoperative RT 36Gy; Radiation: Preoperative RT 50Gy; Radiation: Postoperative RT 50-66Gy; Radiation: RT 36Gy
• Brief Summary: To prospectively study commonly used local treatment approaches in Myxoid Liposarcoma (MLS)…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04699292

 

CLINICAL TRIALS – (ACTIVE, NOT RECRUITING):

A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine

• Locations: UNITED STATES & INTERNATIONAL (See link below for various location options.)
• Status: ACTIVE, NOT RECRUITING
• Phase: 2
• Conditions: Solid Tumor
• Intervention/Treatment: Drug:  Brigimadlin
• Brief Summary: This study is to find out how well people with solid tumours tolerate long-term treatment with brigimadlin. Brigimadlin is a MDM2 inhibitor that was being developed to treat cancer.
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06619509

 

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i)

• Locations: UNITED STATES & INTERNATIONAL (See link below for various location options.)
• Status: ACTIVE, NOT RECRUITING
• Phase: 2
• Conditions: Liposarcoma; Prostate Cancer; Breast Neoplasms; Adenocarcinoma of Lung
• Interventions Drug: PF-07220060; Combination Product: Letrozole; Combination Product: Fulvestrant; Drug:Midazolam; Combination Product: Enzalutamide
• Brief Summary: This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and then in combination with endocrine therapy…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04557449

 

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

• Locations: Texas Children’s Hospital, Houston, Texas, 77030, United States
• Status: ACTIVE, NOT RECRUITING
• Phase: 1
• Conditions: Liver Cancer; Rhabdomyosarcoma; Malignant Rhabdoid Tumor; Liposarcoma; Wilms Tumor; Yolk Sac Tumor
• Interventions Genetic: AGAR T cells
• Brief Summary: Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment. This research study uses special immune system cells called AGAR T cells, a new experimental treatment…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04377932

 

BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (DUET-1)

• Locations: UNITED STATES: Baylor Scott and White Research Institute, Dallas, Texas, 75246, United States; University of Texas MD Anderson Cancer Center, Houston, Texas, 77030-4008, United States; Froedtert and Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States; UNITED KINGDOM: Beatson Institute for Cancer Research Wolfson Wohl Cancer Research Centre
  Glasgow, United Kingdom, G61 1BD; University College London Hospitals NHS Foundation Trust
  London, United Kingdom, NW1 2PG; The Royal Marsden NHS Foundation Trust London, United Kingdom, SW3 6JJ
• Status: ACTIVE, NOT RECRUITING
• Phase: 1/2
• Conditions: Hepatocellular Carcinoma; Squamous Cell Carcinoma of the Lung; Merkel Cell Carcinoma; Myxoid/Round Cell Liposarcoma
• Interventions Biological: CAR-GPC3 T Cells
• Brief Summary: This is a first-in-human (FIH), Phase 1/2, open-label, multicenter study to assess safety and determine the recommended Phase 2 dose (RP2D) of BOXR1030 administration after lymphodepleting chemotherapy (LD chemotherapy) in subjects with glypican-3 positive (GPC3+) advanced solid tumors…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05120271

 

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

• Locations: Krankenhaus Nordwest, Frankfurt, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Universitatsklinikum Tubingen, Tubingen, Germany
• Status: ACTIVE, NOT RECRUITING
• Conditions: Melanoma (Skin); Triple-Negative Breast Cancer; Non-Small Cell Lung Cancer; Synovial Sarcoma; Myxoid Liposarcoma; Colorectal Cancer
• Interventions Biological: PeptiCRAd-1; Drug: Cyclophosphamide; Drug: Pembrolizumab
• Brief Summary: This study is being conducted to explore the immunological mechanism of action of Peptide-coated Conditionally Replicating Adenovirus-1 (PeptiCRAd-1) plus Checkpoint inhibitor (CPI) therapy in multiple cancer types, as well as to obtain early information on the safety of this combination therapy…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05492682

 

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors

• Locations: Houston Methodist Hospital, Houston, Texas, 77030, United States
• Status: ACTIVE, NOT RECRUITING
• Phase: 1
• Conditions: Liver Cell Carcinoma; Solid Tumor; Wilms Tumor; Malignant Rhabdoid Tumor; Yolk Sac Tumor; Rhabdomyosarcoma; Liposarcoma; Embryonal Sarcoma of the Liver
• Interventions Genetic: CATCH T cells
• Brief Summary: Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment. This research study uses special immune system cells called CATCH T cells, a new experimental treatment…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05103631

 

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

• Locations: UNITED STATES & CANADA (See link below for various location options.)
• Status: ACTIVE, NOT RECRUITING
• Phase: 2
• Conditions: Locally Advanced Extraskeletal Myxoid Chondrosarcoma; Locally Advanced Leiomyosarcoma; Locally Advanced Liposarcoma; Locally Advanced Undifferentiated Pleomorphic Sarcoma; Locally Advanced Unresectable Soft Tissue Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma
• Interventions Procedure: Biopsy; Procedure: Biospecimen Collection; Drug: Cabozantinib; Procedure:Computed Tomography; Biological: Ipilimumab; Procedure: Magnetic Resonance Imaging; Biological:Nivolumab
• Brief Summary: This phase II trial compares the effect of immunotherapy with ipilimumab and nivolumab alone to their combination with cabozantinib in treating patients with soft tissue sarcoma that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced)…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05836571

 

Study of the CHK1 Inhibitor BBI-355, an EcDNA-directed Therapy (ecDTx), in Subjects with Tumors with Oncogene Amplifications (POTENTIATE)

• Locations: See link below for various location options.
• Status: ACTIVE, NOT RECRUITING
• Conditions: Non-small Cell Lung Cancer; Non-Small Cell Lung Adenocarcinoma; Non-Small Cell Squamous Lung Cancer; Head and Neck Squamous Cell Carcinoma; Esophageal Cancer; Gastric Cancer; Breast Cancer; Bladder Cancer; Ovarian Cancer; Endometrial Cancer; Liposarcoma
• Interventions Drug: BBI-355; Drug: Erlotinib; Drug: Futibatinib
• Brief Summary: BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx). This is a first-in-human, open-label, 3-part, Phase 1/2 study to determine the safety profile and identify the maximum tolerated dose and recommended Phase 2 dose of BBI-355 administered as a single agent or in combination with select therapies…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05827614

 

SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma

• Locations: University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado, 80045, United States; Mayo Clinic Florida, Jacksonville, Florida, 32224, United States; Northwestern University, Chicago, Illinois, 60611, United States; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, 02114, United States; Washington University School of Medicine, Saint Louis, Missouri, 63129, United States; Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States; Duke University, Durham, North Carolina, 27710, United States; Oregon Health & Science University, Portland, Oregon, 97239, United States; University of Washington, Seattle, Washington, 98109, United States
• Status: ACTIVE, NOT RECRUITING
• Phase: 3
• Conditions: Advanced Dedifferentiated Liposarcoma
• Interventions Drug: Abemaciclib; Drug: Placebo
• Brief Summary: This is a Phase 3 randomized double-blind study of abemaciclib versus placebo. Patients with progression of disease will cross over to open label abemaciclib… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04967521

 

A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma

• Locations: Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, 07920, United States; Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, 07748, United States; Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, 07645, United States; Memorial Sloan Kettering Suffolk – Commack (Limited Protocol Activities), Commack, New York, 11725, United States; Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, 10604, United States; Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States; Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre, New York, 11553, United States
• Status: ACTIVE, NOT RECRUITING
• Phase: 2
• Conditions: Dedifferentiated Liposarcoma; Soft Tissue Sarcoma; Sarcoma,Soft Tissue; Sarcoma; Recurrent Dedifferentiated Liposarcoma; Unresectable Dedifferentiated Liposarcoma; Metastatic Dedifferentiated Liposarcoma
• Interventions Drug: Etrumadenant; Drug: Zimberelimab
• Brief Summary: Participants will have a diagnosis of dedifferentiated liposarcoma (DDLS) that has spread beyond its original location (advanced)…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05886634

 

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

• Locations: See link below for various location options.
• Status: ACTIVE, NOT RECRUITING
• Phase: 2
• Conditions: Synovial Sarcoma; Myxoid Liposarcoma
• Interventions Genetic: afamitresgene autoleucel (previously ADP-A2M4)
• Brief Summary: This is a study to investigate the efficacy and safety of ADP-A2M4 in HLA-A*02 eligible and MAGE-A4 positive subjects with metastatic or inoperable (advanced) Synovial Sarcoma (Cohort 1, 2 and 3 ) or MRCLS (Cohort 1) …
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04044768

 

Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (DOSa)

• Locations: M D Anderson Cancer Center, Houston, Texas, 77030, United States
• Status: ACTIVE, NOT RECRUITING
• Phase: 2
• Conditions: Metastatic Angiosarcoma; Metastatic Dedifferentiated Liposarcoma; Metastatic Osteosarcoma; Recurrent Angiosarcoma; Recurrent Dedifferentiated Liposarcoma; Recurrent Osteosarcoma; Refractory Dedifferentiated Liposarcoma; Refractory Osteosarcoma
• Interventions Biological: Durvalumab; Biological: Oleclumab
• Brief Summary: This phase II trial investigates how well oleclumab and durvalumab work in treating patients with sarcoma that has come back (recurrent) or does not respond to treatment (refractory) or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as oleclumab and durvalumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread…
  For up-to-date information including open recruiting locations and eligibility, click here:STUDY: NCT04668300

 

Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma

• Locations: See link below for various location options.
• Status: ACTIVE, NOT RECRUITING
• Conditions: Advanced Dedifferentiated Liposarcoma; Locally Advanced Dedifferentiated Liposarcoma; Metastatic Dedifferentiated Liposarcoma; Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Unresectable Dedifferentiated Liposarcoma
• Interventions Drug: Palbociclib; Biological: Cemiplimab; Procedure: Magnetic Resonance Imaging; Procedure:Computed Tomography; Procedure: Biospecimen collection; Other: Questionnaire Administration
• Brief Summary: This phase II trial compares the effect of treatment with palbociclib alone to treatment with palbociclib plus cemiplimab for treating patients with dedifferentiated liposarcoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) …
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05694871

 

Updated 4/17/2026